News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Symbollon Pharmaceuticals (SYMBA) Begins to Build Retail Broker Network


6/16/2010 1:08:10 PM

MEDFIELD, MA--(Marketwire - June 16, 2010) -

Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) (www.symbollon.com) is pleased to announce that it has begun to build its retail broker network for Iogen™. New England Vitamin Brokers has agreed to join the Symbollon team to represent Iogen in the New England region. New England Vitamin Brokers provides extensive coverage to all vitamin stores and retail chains in the natural food business. New England Vitamin Brokers is led by Michael Goolkasian, a veteran of the dietary supplement retail business. Iogen is the first dietary supplement formulated to promote breast health for women. Iogen has been clinically tested in over 2,000 women with fibrocystic breast disease, including breast pain and tenderness and benign breast lumps and cysts.

"We are excited to join forces Michael and his group of brokers," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "Through New England Vitamin Brokers we anticipate broad penetration of the New England retail market. Their years of experience representing dietary supplements in the New England area will be of great help to Iogen as we start to expand into the retail market. We will continue to pursue additional retail distribution channels for our product. We are committed to making Iogen available in as many outlets as possible so every woman who has interest in improving her breast health has easy access to Iogen."

"New England Vitamin Brokers is proud to add Iogen to its quality offering of vitamins and other supplements," noted Michael Goolkasian, Director of New England Vitamin Brokers. "Iogen is a truly unique product supported by extensive clinical data. We anticipate that Iogen will be successful in addressing the unmet need for a safe and effective product to improve breast health."

About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)
Symbollon is a specialty life science company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. Iogen is a dietary supplement formulated for women suffering from the symptoms of fibrocystic breast disease, including breast pain and tenderness and benign breast lumps and cysts. For more information about Symbollon, please visit the company's website at http://www.symbollon.com. For more information about Iogen, please visit http://www.buyiogen.com.

Forward Looking Statement This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to successfully commercialize iogen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) Symbollon will be able to commercialize other products and (vi) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.


Contact:
Premier Media Service Inc.
Kelly Black
President
866-216-8814

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES